Transcatheter aortic valve implantation in patients with severe symptomatic aortic valve stenosis: systematic review of cost-effectiveness analysis.
Phatcharaphorn ChotnoppharatphattharaVoratima YoodeeSuthinee TaesotikulJirawit YadeeUnchalee PermsuwanPublished in: The European journal of health economics : HEPAC : health economics in prevention and care (2022)
TAVI is potentially a cost-effective alternative to surgical aortic valve replacement (SAVR) for patients with operable AS with low, intermediate or high risk compared with medical management (MM) for patients with inoperable AS. TAVI was associated with a significant gain in quality-adjusted life-years in almost all studies compared to either SAVR or MM. TAVI is a costly procedure; therefore, justifying its cost-effectiveness depends on the acceptable threshold in each country.
Keyphrases
- transcatheter aortic valve implantation
- aortic valve
- aortic valve replacement
- aortic stenosis
- systematic review
- transcatheter aortic valve replacement
- meta analyses
- healthcare
- ejection fraction
- early onset
- randomized controlled trial
- squamous cell carcinoma
- left ventricular
- quality improvement
- drug induced
- locally advanced
- coronary artery disease
- heart failure
- atrial fibrillation